Genocea Biosciences Inc., of Cambridge, Mass., said findings from a pilot study involving a retrospective analysis of 10 checkpoint inhibitor (CPI)-treated patients' T-cell responses to 23 known tumor-associated antigens support the potential of ATLAS, the firm's rapid antigen identification screening system, to profile responses to immunotherapies for cancer.